Open Access
Open access
Molecules, volume 27, issue 3, pages 628

Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2

Popov Alexander 1
, 
Klimovich Anna 1
, 
Styshova Olga 1, 2
, 
Tsybulsky Alexander 2
, 
Hushpulian Dmitry 2, 3
, 
Osipyants Andrey 2
, 
Khristichenko Anna 4
, 
Kazakov Sergey 5
, 
Ahuja Manuj 6
, 
Kaidery Navneet 6
, 
Thomas Bobby 6
, 
Tishkov Vladimir I. 7, 8, 9
, 
Brown Abraham 10
, 
Gazaryan Irina 3, 5, 8, 9
, 
Poloznikov Andrey 3
1
 
2
 
3
 
4
 
5
 
Department of Chemistry and Physical Sciences, Dyson College of Art and Sciences, Pace University, 861 Bedford Road, Pleasantville, NJ 10570, USA | 
6
 
Departments of Pediatrics, Darby Research Institute, Neurosciencec, Drug Discovery, Medical University of South Carolina, Charleston, SC 29425, USA | 
7
 
8
 
9
 
10
 
Department of Anatomy Cell Biology, New York Medical College, 15 Dana Road, Valhalla, NY 10595, USA | 
Publication type: Journal Article
Publication date: 2022-01-19
Journal: Molecules
Quartile SCImago
Q1
Quartile WOS
Q2
Impact factor: 4.6
ISSN: 14203049
Organic Chemistry
Drug Discovery
Physical and Theoretical Chemistry
Pharmaceutical Science
Molecular Medicine
Analytical Chemistry
Chemistry (miscellaneous)
Abstract

Ginsenoside Rh2 increases the efficacy of doxorubicin (DOX) treatment in murine models of solid and ascites Ehrlich’s adenocarcinoma. In a solid tumor model (treatment commencing 7 days after inoculation), DOX + Rh2 co-treatment was significantly more efficacious than DOX alone. If treatment was started 24 h after inoculation, the inhibition of tumor growth of a solid tumor for the DOX + Rh2 co-treatment group was complete. Furthermore, survival in the ascites model was dramatically higher for the DOX + Rh2 co-treatment group than for DOX alone. Mechanisms underlying the combined DOX and Rh2 effects were studied in primary Ehrlich’s adenocarcinoma-derived cells and healthy mice’s splenocytes. Despite the previously established Rh2 pro-oxidant activity, DOX + Rh2 co-treatment revealed no increase in ROS compared to DOX treatment alone. However, DOX + Rh2 treatment was more effective in suppressing Ehrlich adenocarcinoma cell adhesion than either treatment alone. We hypothesize that the benefits of DOX + Rh2 combination treatment are due to the suppression of tumor cell attachment/invasion that might be effective in preventing metastatic spread of tumor cells. Ginsenoside Rh2 was found to be a modest activator in a Neh2-luc reporter assay, suggesting that Rh2 can activate the Nrf2-driven antioxidant program. Rh2-induced direct activation of Nrf2 might provide additional benefits by minimizing DOX toxicity towards non-cancerous cells.

By date By citations
By date By citations

Citations by journals

1
2
Phytomedicine
Phytomedicine, 2, 50%
Phytomedicine
2 publications, 50%
Frontiers in Pharmacology
Frontiers in Pharmacology, 1, 25%
Frontiers in Pharmacology
1 publication, 25%
Applied Mathematics and Nonlinear Sciences
Applied Mathematics and Nonlinear Sciences, 1, 25%
Applied Mathematics and Nonlinear Sciences
1 publication, 25%
1
2

Citations by publishers

1
2
Elsevier
Elsevier, 2, 50%
Elsevier
2 publications, 50%
Frontiers Media S.A.
Frontiers Media S.A., 1, 25%
Frontiers Media S.A.
1 publication, 25%
Walter de Gruyter
Walter de Gruyter, 1, 25%
Walter de Gruyter
1 publication, 25%
1
2
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Popov A. et al. Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2 // Molecules. 2022. Vol. 27. No. 3. p. 628.
GOST all authors (up to 50) Copy
Popov A., Klimovich A., Styshova O., Tsybulsky A., Hushpulian D., Osipyants A., Khristichenko A., Kazakov S., Ahuja M., Kaidery N., Thomas B., Tishkov V. I., Brown A., Gazaryan I., Poloznikov A. Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2 // Molecules. 2022. Vol. 27. No. 3. p. 628.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/molecules27030628
UR - https://doi.org/10.3390%2Fmolecules27030628
TI - Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2
T2 - Molecules
AU - Popov, Alexander
AU - Klimovich, Anna
AU - Styshova, Olga
AU - Tsybulsky, Alexander
AU - Hushpulian, Dmitry
AU - Osipyants, Andrey
AU - Khristichenko, Anna
AU - Ahuja, Manuj
AU - Kaidery, Navneet
AU - Thomas, Bobby
AU - Gazaryan, Irina
AU - Poloznikov, Andrey
AU - Kazakov, Sergey
AU - Brown, Abraham
AU - Tishkov, Vladimir I.
PY - 2022
DA - 2022/01/19 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 628
IS - 3
VL - 27
PMID - 35163891
SN - 1420-3049
ER -
BibTex |
Cite this
BibTex Copy
@article{2022_Popov,
author = {Alexander Popov and Anna Klimovich and Olga Styshova and Alexander Tsybulsky and Dmitry Hushpulian and Andrey Osipyants and Anna Khristichenko and Manuj Ahuja and Navneet Kaidery and Bobby Thomas and Irina Gazaryan and Andrey Poloznikov and Sergey Kazakov and Abraham Brown and Vladimir I. Tishkov},
title = {Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2},
journal = {Molecules},
year = {2022},
volume = {27},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {jan},
url = {https://doi.org/10.3390%2Fmolecules27030628},
number = {3},
pages = {628},
doi = {10.3390/molecules27030628}
}
MLA
Cite this
MLA Copy
Popov, Alexander, et al. “Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2.” Molecules, vol. 27, no. 3, Jan. 2022, p. 628. https://doi.org/10.3390%2Fmolecules27030628.
Found error?